4D Molecular Therapeutics (NASDAQ:FDMT) Insider Scott Bizily Sells 1,635 Shares of Stock

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) insider Scott Bizily sold 1,635 shares of the stock in a transaction dated Monday, November 17th. The stock was sold at an average price of $10.59, for a total transaction of $17,314.65. Following the sale, the insider owned 3,594 shares of the company’s stock, valued at $38,060.46. This trade represents a 31.27% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Scott Bizily also recently made the following trade(s):

• On Friday, October 24th, Scott Bizily sold 2,678 shares of 4D Molecular Therapeutics stock. The shares were sold at an average price of $12.00, for a total value of $32,136.00.
• On Thursday, October 16th, Scott Bizily sold 1,635 shares of 4D Molecular Therapeutics stock. The shares were sold at an average price of $10.17, for a total value of $16,627.95.
• On Thursday, October 9th, Scott Bizily sold 2,408 shares of 4D Molecular Therapeutics stock. The stock was sold at an average price of $10.00, for a total value of $24,080.00.
• On Tuesday, September 23rd, Scott Bizily sold 2,407 shares of 4D Molecular Therapeutics stock. The shares were sold at an average price of $8.00, for a total value of $19,256.00.

4D Molecular Therapeutics Price Performance

Shares of NASDAQ:FDMT traded up $0.71 during trading on Wednesday, reaching $10.80. The company had a trading volume of 904,864 shares, compared to its average volume of 1,057,282. 4D Molecular Therapeutics, Inc. has a fifty-two week low of $2.23 and a fifty-two week high of $12.34. The stock’s fifty day moving average price is $9.54 and its 200 day moving average price is $6.43. The firm has a market capitalization of $617.00 million, a price-to-earnings ratio of -2.88 and a beta of 2.96.

4D Molecular Therapeutics (NASDAQ:FDMT) last posted its quarterly earnings data on Monday, November 10th. The company reported ($1.01) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.02) by $0.01. 4D Molecular Therapeutics had a negative net margin of 174,314.17% and a negative return on equity of 47.27%. The firm had revenue of $0.09 million for the quarter, compared to analyst estimates of $0.40 million. On average, equities analysts anticipate that 4D Molecular Therapeutics, Inc. will post -2.84 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts recently weighed in on the company. Wall Street Zen raised 4D Molecular Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday. Royal Bank Of Canada increased their target price on 4D Molecular Therapeutics from $26.00 to $32.00 and gave the company an “outperform” rating in a report on Tuesday, November 11th. Barclays lowered their price target on shares of 4D Molecular Therapeutics from $38.00 to $33.00 and set an “overweight” rating for the company in a report on Tuesday, November 11th. Chardan Capital upped their target price on 4D Molecular Therapeutics from $25.00 to $26.00 and gave the company a “buy” rating in a research note on Tuesday, November 11th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research note on Wednesday, October 8th. Eight equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, 4D Molecular Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $28.70.

Institutional Trading of 4D Molecular Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the business. Armistice Capital LLC increased its holdings in 4D Molecular Therapeutics by 265.3% in the 3rd quarter. Armistice Capital LLC now owns 1,096,000 shares of the company’s stock valued at $9,524,000 after purchasing an additional 796,000 shares in the last quarter. Wexford Capital LP acquired a new position in shares of 4D Molecular Therapeutics during the third quarter worth about $41,000. Prelude Capital Management LLC boosted its position in shares of 4D Molecular Therapeutics by 11.1% in the third quarter. Prelude Capital Management LLC now owns 23,000 shares of the company’s stock worth $200,000 after buying an additional 2,300 shares during the period. Parkman Healthcare Partners LLC purchased a new stake in shares of 4D Molecular Therapeutics in the third quarter worth about $1,738,000. Finally, Brevan Howard Capital Management LP acquired a new stake in shares of 4D Molecular Therapeutics in the third quarter valued at about $143,000. 99.27% of the stock is owned by hedge funds and other institutional investors.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.